Lipocine Reports Positive Phase 3 Safety for LPCN 1154
November 18, 2025
Lipocine Inc., a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, announced the completion of a scheduled independent
